Blake Insomnia Therapeutics Inc and Sajo Consulting LLC have entered into a Letter of Intent to provide joint development and commercialization of Zleepax, in combination with formulations to produce a series of oral drug products to aid in the treatment of insomnia. This venture looks to develop a product to treat transient insomnia through the mechanism of Blake’s proprietary formula.
Zleepax is for treatment of insomnia and will be the first new drug investment made by Blake. The pivotal Phase II clinical trial is planned for the second quarter of 2017 and pending the regulatory submission of the New Drug Application in Canada. With a successful filing and NDA approval, the product is expected to be launched in the United States in 2022 with international filings to follow.
This collaboration with Sajo signifies Blake’s strategic move into the new drug development field with focus on applying improvements to non-benzodiazepine drugs in the treatment of insomnia. The joint development will capitalize on the reputation Sajo Consulting has developed as a consultant in the medical and pharmaceutical industries. Blake and Sajo will jointly develop strong molecular pipelines for pairing with Zleepax in its product bases. Blake will be the exclusive provider of Zleepax and will further work with Sajo to develop additional new Zleepax products to capitalize on the insomnia markets.
Blake CEO Birger Jan Olsen says in a release: “We are excited about the agreement with Sajo as they have the required expertise and knowledge to carry out Phase 2 clinical trial and we are looking forward working together”.
Blake is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. The patent-pending ZLX-1 compound is marketed under the brand name, Zleepax.
